牛津及阿斯利康噴鼻式新冠疫苗初期臨牀測試未如理想
由英國牛津大學及藥廠阿斯利康(AZN.US)聯合研發的噴鼻式新冠疫苗,初期臨牀測試未如理想。研究人員認爲,噴鼻式疫苗仍然是一個好方向,但要成爲可靠的疫苗選項,仍然存在挑戰。
研究招募30名從未接種任何疫苗的人士,以及12名曾接種兩針的人士進行測試,發現在使用兩劑疫苗後,只有少數人的呼吸道有產生黏膜抗體,但水平亦不高。在血液中量度到的抗體水平,亦較肌肉注射的疫苗低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.